These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
211 related articles for article (PubMed ID: 8355419)
1. Impaired fibrinolysis in hypertension and obesity due to high plasminogen activator inhibitor-1 level in plasma. Urano T; Kojima Y; Takahashi M; Serizawa K; Sakakibara K; Takada Y; Takada A Jpn J Physiol; 1993; 43(2):221-8. PubMed ID: 8355419 [TBL] [Abstract][Full Text] [Related]
2. Relationships of blood pressure to fibrinolysis: influence of anthropometry, metabolic profile and behavioural variables. Cigolini M; Targher G; Seidell JC; Tonoli M; Schiavon R; Agostino G; De Sandre G J Hypertens; 1995 Jun; 13(6):659-66. PubMed ID: 7594424 [TBL] [Abstract][Full Text] [Related]
3. The effect of chronic allograft rejection on plasma regulators of fibrinolysis. Perkowska A; Elhasade A; Durlik M; Placha G; Gałazka Z; Lao M; Gaciong Z Ann Transplant; 2002; 7(1):44-51. PubMed ID: 12221903 [TBL] [Abstract][Full Text] [Related]
4. Relationships between euglobulin clot lysis time and the plasma levels of tissue plasminogen activator and plasminogen activator inhibitor 1. Urano T; Sakakibara K; Rydzewski A; Urano S; Takada Y; Takada A Thromb Haemost; 1990 Feb; 63(1):82-6. PubMed ID: 2111051 [TBL] [Abstract][Full Text] [Related]
6. Hypertension and the metabolic cardiovascular syndrome: special reference to premenopausal women. Os I; Nordby G J Cardiovasc Pharmacol; 1992; 20 Suppl 8():S15-21. PubMed ID: 1283764 [TBL] [Abstract][Full Text] [Related]
7. Lower androgenicity is associated with higher plasma levels of prothrombotic factors irrespective of age, obesity, body fat distribution, and related metabolic parameters in men. De Pergola G; De Mitrio V; Sciaraffia M; Pannacciulli N; Minenna A; Giorgino F; Petronelli M; Laudadio E; Giorgino R Metabolism; 1997 Nov; 46(11):1287-93. PubMed ID: 9361687 [TBL] [Abstract][Full Text] [Related]
9. Lipoprotein(a), tissue plasminogen activator and plasminogen activator inhibitor 1 levels in hyperlipidaemic patients in Kuwait. Akanji AO; Abdullah A; Tahzeeb S Eur J Clin Invest; 1997 May; 27(5):380-6. PubMed ID: 9179544 [TBL] [Abstract][Full Text] [Related]
10. [Relationship of age, sex, body weight, smoking, blood lipids and fibrinolytic activities in healthy subjects]. Xiong X; Wang Z; Zhao S Hunan Yi Ke Da Xue Xue Bao; 1999; 24(1):65-7. PubMed ID: 11938745 [TBL] [Abstract][Full Text] [Related]
11. [Selected new atherosclerosis risk factors and markers of fibrinolysis in children and adolescents with obesity, hypertension and diabetes]. Głowińska B; Urban M; Koput A; Galar M Przegl Lek; 2003; 60(1):12-7. PubMed ID: 12884639 [TBL] [Abstract][Full Text] [Related]
12. Hypo-fibrinolysis in patients with hypertension and elevated cholesterol. Jansson JH; Johansson B; Boman K; Nilsson TK J Intern Med; 1991 Apr; 229(4):309-16. PubMed ID: 1902868 [TBL] [Abstract][Full Text] [Related]
13. Recognition of Plasminogen Activator Inhibitor Type 1 as the Primary Regulator of Fibrinolysis. Urano T; Suzuki Y; Iwaki T; Sano H; Honkura N; Castellino FJ Curr Drug Targets; 2019; 20(16):1695-1701. PubMed ID: 31309890 [TBL] [Abstract][Full Text] [Related]
14. Association of blood pressure with fibrinolytic potential in the Framingham offspring population. Poli KA; Tofler GH; Larson MG; Evans JC; Sutherland PA; Lipinska I; Mittleman MA; Muller JE; D'Agostino RB; Wilson PW; Levy D Circulation; 2000 Jan; 101(3):264-9. PubMed ID: 10645922 [TBL] [Abstract][Full Text] [Related]
15. Impaired fibrinolysis and insulin resistance in patients with hypertension. Jeng JR; Sheu WH; Jeng CY; Huang SH; Shieh SM Am J Hypertens; 1996 May; 9(5):484-90. PubMed ID: 8735180 [TBL] [Abstract][Full Text] [Related]
16. In vitro clot lysis as a potential indicator of thrombus resistance to fibrinolysis--study in healthy subjects and correlation with blood fibrinolytic parameters. Colucci M; Scopece S; Gelato AV; Dimonte D; Semeraro N Thromb Haemost; 1997 Apr; 77(4):725-9. PubMed ID: 9134650 [TBL] [Abstract][Full Text] [Related]
17. Overweight/obesity, smoking, and heavy alcohol consumption are important determinants of plasma PAI-1 levels in healthy men. Sasaki A; Kurisu A; Ohno M; Ikeda Y Am J Med Sci; 2001 Jul; 322(1):19-23. PubMed ID: 11465242 [TBL] [Abstract][Full Text] [Related]
18. Increased plasminogen activator inhibitor activity in survivors of myocardial infarction is associated with metabolic risk factors of atherosclerosis. Keber I; Keber D Haemostasis; 1992; 22(4):187-94. PubMed ID: 1468721 [TBL] [Abstract][Full Text] [Related]
19. Plasma fibrinolytic activators and their inhibitors in women suffering from early recurrent abortion of unknown etiology. Gris JC; Neveu S; Mares P; Biron C; Hedon B; Schved JF J Lab Clin Med; 1993 Nov; 122(5):606-15. PubMed ID: 8228580 [TBL] [Abstract][Full Text] [Related]
20. Impaired fibrinolytic compensation for hypercoagulability in obese patients with type 2 diabetes: association with increased plasminogen activator inhibitor-1. Aso Y; Matsumoto S; Fujiwara Y; Tayama K; Inukai T; Takemura Y Metabolism; 2002 Apr; 51(4):471-6. PubMed ID: 11912556 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]